Jurisdiction - China
China – Paul, Weiss Advises KKR on USD65m investment into CCBC.


13 April, 2012
China Cord Blood Corporation (NYSE: CO), the largest cord blood banking operator in China ("CCBC") and KKR China Healthcare Investment Limited ("KKR") announced on April 11, 2012 that they have entered into a purchase agreement for an issuance to KKR of USD65 million principal amount notes convertible into CCBC common stock. CCBC is listed on the New York Stock Exchange since 2009 and was the first licensed cord blood banking operator in China. The investment will be used to support CCBC's business expansion and to capitalize on China’s fast growing healthcare services industry. The transaction is described in the attached press release. 
Paul, Weiss represented KKR in this transaction. The Paul, Weiss team included corporate partners Jack Lange, Mark Bergman, Tracey Zaccone and Mark Mendelsohn, counsel Richard Elliott and associates Vivek Baid, Patricia Vaz de Almeida and Sue Yang, tax partner David Sicular and tax associate Joy Zhang.
For further information, please contact:
Denisha Trouard, Paul, Weiss, Rifkind, Wharton & Garrison


Leave a Reply

You must be logged in to post a comment.